<DOC>
	<DOCNO>NCT00666406</DOCNO>
	<brief_summary>The purpose study compare pharmacokinetic parameter safety Advate rAHF-PFM versus Recombinate rAHF well describe previously treat patient severe hemophilia A ( factor VIII level &lt; 1 % ) .</brief_summary>
	<brief_title>Pharmacokinetic Comparison Advate rAHF-PFM With Recombinate rAHF Patients With Severe Hemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Signed informed consent obtain participant legally authorize representative 1560 year old Factor VIII level &lt; 1 % document previously measure factor VIII genotyping Previously treat factor VIII concentrate ( ) minimum least 150 exposure day ( document study site investigator ) prior study entry Observed decrease efficacy subject and/or treat physician switch Recombinate rAHF Advate rAHFPFM The participant detectable factor VIII inhibitor screening , titer &gt; = 0.4 Bethesda Unit ( BU ) ( Nijmegen modification Bethesda Assay ) measure local central laboratory The participant know hypersensitivity mouse hamster proteins The participant participate another investigational drug study within 30 day prior screen The participant identify investigator unable unwilling cooperate study procedure</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>